Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Labrys Biologics begins operations with $31mm Series A financing, migraine antibody from Pfizer
15 Apr 2013
Lead investor venBio has teamed with Canaan Partners, InterWest Partners, Sofinnova Ventures, and one other undisclosed backer in the $31mm Series A financing for Labrys Biologics Inc., which has concurrently licensed from Pfizer the Phase I antibody RN307. Labrys will advance the candidate, which targets the calcitonin gene-related peptide (CGRP), into Phase II for chronic migraine later this year. VenBio's managing director Corey Goodman, PhD (also a former Pfizer exec), is Labrys' founder. Representatives from Canaan Partners, InterWest, and Sofinnova have joined the start-up’s board.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?